Fulgent Genetics (FLGT) to Release Quarterly Earnings on Friday

Posted by AM Reporter Staff on May 1st, 2024

Fulgent Genetics (NASDAQ:FLGT – Get Free Report) is set to post its quarterly earnings results before the market opens on Friday, May 3rd. Analysts expect Fulgent Genetics to post earnings of ($0.33) per share for the quarter. Fulgent Genetics has set its FY24 guidance at -$1.05 EPS and its FY 2024 guidance at -1.050–1.050 EPS.Individual that are interested in participating in the company’s earnings conference call can do so using this link.

Fulgent Genetics (NASDAQ:FLGT – Get Free Report) last posted its quarterly earnings results on Wednesday, February 28th. The company reported ($0.02) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.63) by $0.61. The firm had revenue of $70.51 million for the quarter, compared to analyst estimates of $67.14 million. Fulgent Genetics had a negative net margin of 58.03% and a negative return on equity of 3.04%. On average, analysts expect Fulgent Genetics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Fulgent Genetics Trading Down 1.1 %

FLGT stock opened at $20.35 on Wednesday. The firm has a 50-day moving average of $21.95 and a two-hundred day moving average of $25.06. Fulgent Genetics has a 12 month low of $19.88 and a 12 month high of $44.09. The company has a market cap of $608.47 million, a price-to-earnings ratio of -3.61 and a beta of 1.43.

Analysts Set New Price Targets

Separately, Piper Sandler reduced their price objective on Fulgent Genetics from $28.00 to $25.00 and set a “neutral” rating on the stock in a research report on Wednesday, March 6th.

Check Out Our Latest Stock Report on Fulgent Genetics

Fulgent Genetics Company Profile

(Get Free Report)

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.